JP2013523887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523887A5 JP2013523887A5 JP2013505056A JP2013505056A JP2013523887A5 JP 2013523887 A5 JP2013523887 A5 JP 2013523887A5 JP 2013505056 A JP2013505056 A JP 2013505056A JP 2013505056 A JP2013505056 A JP 2013505056A JP 2013523887 A5 JP2013523887 A5 JP 2013523887A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- och
- branched
- lower alkyl
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 14
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- -1 C-5 modified aminocarbonyl pyrimidines Chemical class 0.000 claims description 11
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 8
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 150000002825 nitriles Chemical class 0.000 claims description 7
- 150000003140 primary amides Chemical class 0.000 claims description 7
- 150000003334 secondary amides Chemical class 0.000 claims description 7
- 229940124530 sulfonamide Drugs 0.000 claims description 7
- 150000003456 sulfonamides Chemical class 0.000 claims description 7
- 150000003511 tertiary amides Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 9
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 8
- 108091023037 Aptamer Proteins 0.000 claims 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 150000001540 azides Chemical class 0.000 claims 5
- 238000007385 chemical modification Methods 0.000 claims 5
- 150000003512 tertiary amines Chemical class 0.000 claims 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims 2
- 229940043279 diisopropylamine Drugs 0.000 claims 2
- 230000011987 methylation Effects 0.000 claims 2
- 238000007069 methylation reaction Methods 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000005571 anion exchange chromatography Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- QCVZGSPBPJXJJV-UHFFFAOYSA-N chloro-N-(4-cyano-2-methylbutan-2-yl)-N-propan-2-ylphosphonamidous acid Chemical compound CC(C)N(C(C)(C)CCC#N)P(O)Cl QCVZGSPBPJXJJV-UHFFFAOYSA-N 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229960005215 dichloroacetic acid Drugs 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- 229940048102 triphosphoric acid Drugs 0.000 claims 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N C1Oc(cccc2)c2O1 Chemical compound C1Oc(cccc2)c2O1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- SEKPRWQPUHSEJR-UHFFFAOYSA-N CCC1c(cccc2)c2C=CC=C1 Chemical compound CCC1c(cccc2)c2C=CC=C1 SEKPRWQPUHSEJR-UHFFFAOYSA-N 0.000 description 1
- YOSWATANJKGQPZ-UHFFFAOYSA-N NN(c1ccccc1N1)[IH]1=O Chemical compound NN(c1ccccc1N1)[IH]1=O YOSWATANJKGQPZ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 0 c1cc*cc1 Chemical compound c1cc*cc1 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32314510P | 2010-04-12 | 2010-04-12 | |
| US61/323,145 | 2010-04-12 | ||
| PCT/US2011/032143 WO2011130289A1 (en) | 2010-04-12 | 2011-04-12 | 5-position modified pyrimidines and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041782A Division JP6352324B2 (ja) | 2010-04-12 | 2016-03-04 | ５位修飾ピリミジンとその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523887A JP2013523887A (ja) | 2013-06-17 |
| JP2013523887A5 true JP2013523887A5 (enExample) | 2015-10-08 |
| JP5901610B2 JP5901610B2 (ja) | 2016-04-13 |
Family
ID=44798979
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505029A Expired - Fee Related JP6012591B2 (ja) | 2010-04-12 | 2011-04-12 | β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用 |
| JP2013505056A Active JP5901610B2 (ja) | 2010-04-12 | 2011-04-12 | ５位修飾ピリミジンとその使用 |
| JP2016041782A Active JP6352324B2 (ja) | 2010-04-12 | 2016-03-04 | ５位修飾ピリミジンとその使用 |
| JP2018034436A Active JP7025818B2 (ja) | 2010-04-12 | 2018-02-28 | ５位修飾ピリミジンとその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505029A Expired - Fee Related JP6012591B2 (ja) | 2010-04-12 | 2011-04-12 | β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041782A Active JP6352324B2 (ja) | 2010-04-12 | 2016-03-04 | ５位修飾ピリミジンとその使用 |
| JP2018034436A Active JP7025818B2 (ja) | 2010-04-12 | 2018-02-28 | ５位修飾ピリミジンとその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8598140B2 (enExample) |
| EP (3) | EP3345915B1 (enExample) |
| JP (4) | JP6012591B2 (enExample) |
| KR (4) | KR101952671B1 (enExample) |
| CN (4) | CN102985435B (enExample) |
| AR (1) | AR081452A1 (enExample) |
| AU (2) | AU2011240774B2 (enExample) |
| BR (2) | BR122021003805B8 (enExample) |
| CA (3) | CA2793451A1 (enExample) |
| CO (1) | CO6630139A2 (enExample) |
| DK (1) | DK2558478T3 (enExample) |
| EA (1) | EA022429B1 (enExample) |
| ES (3) | ES2667491T3 (enExample) |
| HK (1) | HK1201740A1 (enExample) |
| IL (5) | IL222339A (enExample) |
| MX (4) | MX2012011779A (enExample) |
| MY (1) | MY160608A (enExample) |
| NO (1) | NO2558478T3 (enExample) |
| NZ (1) | NZ602618A (enExample) |
| PH (1) | PH12012501838A1 (enExample) |
| SG (3) | SG184089A1 (enExample) |
| TW (6) | TWI505833B (enExample) |
| UA (1) | UA105290C2 (enExample) |
| WO (2) | WO2011130289A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993279A (ja) * | 1982-11-17 | 1984-05-29 | 富士通株式会社 | ロボツトによるカ−ド，レシ−ト分離取出し方法 |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8404830B2 (en) * | 2007-07-17 | 2013-03-26 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8598140B2 (en) * | 2010-04-12 | 2013-12-03 | Somalogic, Inc. | Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders |
| CN103492569B (zh) | 2010-11-05 | 2020-04-07 | 米拉根医疗公司 | 碱基经修饰的寡核苷酸 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| EP2646468B1 (en) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| EP2831278B1 (en) * | 2012-03-28 | 2019-05-08 | Somalogic, Inc. | Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions |
| HK1205764A1 (en) | 2012-04-13 | 2015-12-24 | Somalogic, Inc. | Tuberculosis biomarkers and uses thereof |
| WO2014007438A1 (ko) * | 2012-07-02 | 2014-01-09 | 국립대학법인 울산과학기술대학교 산학협력단 | 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물 |
| EP2912182B1 (en) | 2012-10-23 | 2021-12-08 | Caris Science, Inc. | Aptamers and uses thereof |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| US9939443B2 (en) | 2012-12-19 | 2018-04-10 | Caris Life Sciences Switzerland Holdings Gmbh | Compositions and methods for aptamer screening |
| CA2902186C (en) | 2013-03-14 | 2023-04-11 | Somalogic, Inc. | Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions |
| TWI594975B (zh) | 2013-04-24 | 2017-08-11 | 第一三共股份有限公司 | 二羧酸化合物 |
| WO2014177510A2 (en) * | 2013-05-03 | 2014-11-06 | Creabilis Sa | Polymer conjugates of indolocarbazole compounds in the treatment of pruritus |
| GB201312295D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Suppression of itch |
| WO2015035305A1 (en) * | 2013-09-09 | 2015-03-12 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
| CA2924987C (en) * | 2013-09-24 | 2022-08-16 | Somalogic, Inc. | Multiaptamer target detection |
| JP2015062364A (ja) * | 2013-09-25 | 2015-04-09 | Ｎｅｃソリューションイノベータ株式会社 | クレンブテロールに結合する核酸分子およびその用途 |
| JP2015062365A (ja) * | 2013-09-25 | 2015-04-09 | Ｎｅｃソリューションイノベータ株式会社 | ラクトパミンに結合する核酸分子およびその用途 |
| WO2015066001A1 (en) * | 2013-10-29 | 2015-05-07 | Albert Einstein College Of Medicine Of Yeshiva University | Nucleic acid-scaffolded small molecule libraries |
| CN105658658B (zh) * | 2013-11-21 | 2019-11-05 | 私募蛋白质体公司 | 胞苷-5-甲酰胺修饰的核苷酸组合物及其相关方法 |
| RU2686992C2 (ru) * | 2014-03-24 | 2019-05-06 | Рибомик Инк. | Аптамер для fgf2 и его применение |
| NO2718257T3 (enExample) * | 2014-05-30 | 2018-04-14 | ||
| KR102541110B1 (ko) | 2014-08-25 | 2023-06-08 | 에이뮨 테라퓨틱스, 인코퍼레이티드 | 난 단백질 제형 및 이의 제조 방법 |
| CN104561013A (zh) * | 2015-01-05 | 2015-04-29 | 中国人民解放军南京军区福州总医院 | 基于高通量测序技术进行核酸适配体序列优化的方法 |
| EP3414229B1 (en) | 2016-02-09 | 2021-06-16 | Pharmakea, Inc. | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof |
| MX2018011052A (es) * | 2016-03-14 | 2019-01-24 | Somalogic Inc | Compuestos y metodos para la sintesis de fosforamidato de 5-(n-triptamina carboxamida protegida)-2'-desoxiuridina para ser incorporados en una secuencia nucleica. |
| CN107663220B (zh) * | 2016-07-27 | 2020-10-02 | 上海伯豪医学检验所有限公司 | 修饰碱基、包含修饰碱基的核酸、适配体及其应用 |
| WO2018079864A1 (ko) | 2016-10-24 | 2018-05-03 | 김성천 | TNF-α 결합 압타머 및 그것의 치료적 용도 |
| EP4614155A3 (en) | 2016-12-01 | 2025-10-15 | Nautilus Subsidiary, Inc. | Methods of assaying proteins |
| AU2018395430B2 (en) | 2017-12-29 | 2024-05-23 | Nautilus Subsidiary, Inc. | Decoding approaches for protein identification |
| CN108299518A (zh) * | 2018-02-02 | 2018-07-20 | 王成宇 | 一种2`-脱氧-β-尿苷的合成方法 |
| WO2019154410A1 (zh) | 2018-02-12 | 2019-08-15 | 翼高生物科技有限公司 | 针对骨硬化蛋白的适体及其用途 |
| WO2019246289A1 (en) * | 2018-06-22 | 2019-12-26 | Somalogic, Inc. | Improved proteomic multiplex assays |
| EP3942295A1 (en) | 2019-03-22 | 2022-01-26 | Somalogic, Inc. | Reducing intersample analyte variability in complex biological matrices |
| AU2020278570A1 (en) | 2019-05-17 | 2022-01-06 | Somalogic Operating Co., Inc. | Controlling intersample analyte variability in complex biological matrices |
| EP4165549A1 (en) | 2020-06-11 | 2023-04-19 | Nautilus Biotechnology, Inc. | Methods and systems for computational decoding of biological, chemical, and physical entities |
| US12092642B2 (en) | 2021-01-20 | 2024-09-17 | Nautilus Subsidiary, Inc. | Systems and methods for biomolecule quantitation |
| US20220227890A1 (en) | 2021-01-21 | 2022-07-21 | Nautilus Biotechnology, Inc. | Systems and methods for biomolecule preparation |
| IL305336B2 (en) | 2021-03-11 | 2025-09-01 | Nautilus Subsidiary Inc | Systems and methods for preserving biomolecules |
| WO2022199685A1 (zh) | 2021-03-25 | 2022-09-29 | 安沛治疗有限公司 | 具有延长的体内半衰期的核酸分子缀合物 |
| CN113481204B (zh) * | 2021-07-02 | 2022-08-12 | 湖南赛奥维生物技术有限公司 | 一种蛋白的核酸适配体、其衍生物及其应用 |
| EP4399528A1 (en) | 2021-09-09 | 2024-07-17 | Nautilus Subsidiary, Inc. | Characterization and localization of protein modifications |
| EP4405683A1 (en) | 2021-09-22 | 2024-07-31 | Nautilus Subsidiary, Inc. | Methods and systems for determining polypeptide interactions |
| JP2024535224A (ja) | 2021-09-26 | 2024-09-30 | アプタキュア セラピューティクス リミテッド | Ｄｋｋ１に対するアプタマー及びその使用 |
| US20230149883A1 (en) | 2021-11-03 | 2023-05-18 | Nautilus Biotechnology, Inc. | Systems and methods for surface structuring |
| WO2023192917A1 (en) | 2022-03-29 | 2023-10-05 | Nautilus Subsidiary, Inc. | Integrated arrays for single-analyte processes |
| US20230360732A1 (en) | 2022-04-25 | 2023-11-09 | Nautilus Subsidiary, Inc. | Systems and methods for assessing and improving the quality of multiplex molecular assays |
| WO2023250364A1 (en) | 2022-06-21 | 2023-12-28 | Nautilus Subsidiary, Inc. | Method for detecting analytes at sites of optically non-resolvable distances |
| WO2024059655A1 (en) | 2022-09-15 | 2024-03-21 | Nautilus Subsidiary, Inc. | Characterizing accessibility of macromolecule structures |
| WO2024073599A1 (en) | 2022-09-29 | 2024-04-04 | Nautilus Subsidiary, Inc. | Preparation of array surfaces for single-analyte processes |
| WO2024107857A1 (en) | 2022-11-15 | 2024-05-23 | Nautilus Subsidiary, Inc. | Standard polypeptides |
| EP4630816A1 (en) | 2022-12-09 | 2025-10-15 | Nautilus Subsidiary, Inc. | A method comprising performing on a single-analyte array at least 50 cycles of a process |
| EP4634285A1 (en) | 2022-12-15 | 2025-10-22 | Nautilus Subsidiary, Inc. | Inhibition of photon phenomena on single molecule arrays |
| US20240241110A1 (en) | 2023-01-12 | 2024-07-18 | Nautilus Subsidiary, Inc. | Characterization of glycans and glycoconjugates |
| WO2024206122A1 (en) | 2023-03-24 | 2024-10-03 | Nautilus Subsidiary, Inc. | Improved transfer of nanoparticles to array surfaces |
| WO2024216233A1 (en) | 2023-04-13 | 2024-10-17 | Nautilus Subsidiary, Inc. | Artificial proteins for displaying epitopes |
| WO2024228396A1 (ja) * | 2023-05-01 | 2024-11-07 | 株式会社ナティアス | オリゴヌクレオチド合成用の高脂溶性ヌクレオチドビルディングブロックおよびこれを用いたオリゴヌクレオチドの合成 |
| US20240394902A1 (en) | 2023-05-24 | 2024-11-28 | Nautilus Subsidiary, Inc. | Systems and methods for machine vision |
| WO2025128588A1 (en) | 2023-12-11 | 2025-06-19 | Nautilus Subsidiary, Inc. | Methods and compositions of particle-based arrays |
| WO2025137166A1 (en) | 2023-12-20 | 2025-06-26 | Nautilus Subsidiary, Inc. | Fluidic devices for single-analyte assays |
| WO2025199236A1 (en) | 2024-03-22 | 2025-09-25 | Nautilus Subsidiary, Inc. | Plasmonic particle systems for single-analyte assays |
| US20250305034A1 (en) | 2024-04-01 | 2025-10-02 | Nautilus Subsidiary, Inc. | Nanostructures for modulation of analyte conformation |
| CN119792485B (zh) * | 2025-03-17 | 2025-06-24 | 温州医科大学附属口腔医院 | 一种抑菌促修复水凝胶敷料及制备方法 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267171A (en) | 1979-07-02 | 1981-05-12 | The Regents Of The University Of California | C-5 Substituted cytosine nucleosides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4594339A (en) | 1982-04-06 | 1986-06-10 | Sloan-Kettering Institute For Cancer Research | Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides |
| US5599720A (en) | 1982-08-27 | 1997-02-04 | Multilyte Limited | Measurement of analyte concentration |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| DE3329892A1 (de) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
| US4737453A (en) | 1984-12-12 | 1988-04-12 | Immunomedics, Inc. | Sandwich immunoassay utilizing a separation specific binding substance |
| AU4434585A (en) | 1985-03-30 | 1986-10-23 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
| US4752566A (en) | 1985-12-17 | 1988-06-21 | Genetics Institute, Inc. | Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide |
| US5047519A (en) | 1986-07-02 | 1991-09-10 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
| US4997818A (en) | 1987-09-21 | 1991-03-05 | The University Hospital | Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas |
| SE8802173D0 (sv) | 1988-06-10 | 1988-06-10 | Astra Ab | Pyrimidine derivatives |
| KR920701230A (ko) * | 1989-06-05 | 1992-08-11 | 원본미기재 | 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법 |
| US5118672A (en) | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| EP0498843B1 (en) | 1989-10-24 | 1996-06-12 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| ATE119541T1 (de) | 1990-03-13 | 1995-03-15 | Acic Canada Inc | Verfahren zur herstellung von nucleosiden und ihre analogen. |
| WO1991014696A1 (en) | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| US6346611B1 (en) | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5476766A (en) | 1990-06-11 | 1995-12-19 | Nexstar Pharmaceuticals, Inc. | Ligands of thrombin |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US6030776A (en) | 1990-06-11 | 2000-02-29 | Nexstar Pharmaceuticals, Inc. | Parallel SELEX |
| DK0786469T3 (da) | 1990-06-11 | 2006-07-10 | Gilead Sciences Inc | Nukleinsyreligander |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| EP0572529A4 (en) | 1991-02-21 | 1994-11-02 | Gilead Sciences Inc | SPECIFIC APTAMER OF BIOMOLECULES AND PROCESS FOR PRODUCING THE SAME. |
| IE920561A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for thrombin and methods of use |
| US5840867A (en) * | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| EP1256589A3 (en) | 1991-11-26 | 2003-09-17 | Isis Pharmaceuticals, Inc. | Oligomers containing modified pyrimidines |
| US5719273A (en) | 1993-06-14 | 1998-02-17 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide |
| US5580972A (en) | 1993-06-14 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | Purine nucleoside modifications by palladium catalyzed methods |
| US5428149A (en) | 1993-06-14 | 1995-06-27 | Washington State University Research Foundation | Method for palladium catalyzed carbon-carbon coulping and products |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
| JP4899014B2 (ja) * | 1995-06-02 | 2012-03-21 | イーシー・テクノロジー・エルエルシー | 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法 |
| US5962225A (en) | 1995-10-27 | 1999-10-05 | Cygene, Inc. | Methods and compositions for detection of specific nucleotide sequences |
| US5945527A (en) | 1996-05-30 | 1999-08-31 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide |
| US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20060057573A1 (en) | 2002-02-15 | 2006-03-16 | Somalogic, Inc | Methods and reagents for detecting target binding by nucleic acid ligands |
| US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| US6020483A (en) | 1998-09-25 | 2000-02-01 | Nexstar Pharmaceuticals, Inc. | Nucleoside modifications by palladium catalyzed methods |
| US6175001B1 (en) | 1998-10-16 | 2001-01-16 | The Scripps Research Institute | Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same |
| US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
| US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| JP3485023B2 (ja) * | 1999-05-20 | 2004-01-13 | 東亞合成株式会社 | ヌクレオシド化合物 |
| US20030054360A1 (en) * | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
| KR100974917B1 (ko) * | 2000-04-13 | 2010-08-09 | 파마셋 인코포레이티드 | 간염 바이러스 감염 치료를 위한 3'- 또는2'-하이드록시메틸 치환된 뉴클레오시드 유도체 |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| US20030148335A1 (en) | 2001-10-10 | 2003-08-07 | Li Shen | Detecting targets by unique identifier nucleotide tags |
| EP1489171B1 (en) | 2002-03-19 | 2012-10-31 | Fujitsu Limited | Functional molecule and process for producing the same |
| US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
| CA2407825A1 (en) | 2002-10-11 | 2004-04-11 | Andrew J. Simmonds | Trap-tagging: a novel method for the identification and purification of rna-protein complexes |
| AU2004204456A1 (en) | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
| JP4119976B2 (ja) * | 2003-02-07 | 2008-07-16 | 国立大学法人群馬大学 | ５位置換ピリミジンデオキシヌクレオチド誘導体、及びそれを用いた核酸の合成方法 |
| WO2005024042A2 (en) | 2003-09-04 | 2005-03-17 | The Regents Of The University Of California | Aptamers and methods for their in vitro selection and uses thereof |
| US20050227225A1 (en) | 2004-04-07 | 2005-10-13 | Roche Molecular Systems, Inc. | Stabilization of biomolecules in samples |
| CA2562151C (en) | 2004-04-30 | 2016-09-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
| JP2006117542A (ja) * | 2004-10-19 | 2006-05-11 | Pias Arise Kk | 神経成長因子産生抑制剤、並びにその神経成長因子産生抑制剤を配合した皮膚外用剤、化粧料、医薬部外品、痒み予防及び治療剤、及びアトピー性皮膚炎治療剤 |
| EP1828217A2 (en) | 2004-12-16 | 2007-09-05 | Febit Biotech GmbH | Polymerase-independent analysis of the sequence of polynucleotides |
| WO2007044427A2 (en) | 2005-10-05 | 2007-04-19 | Panomics, Inc. | Detection of nucleic acids from whole blood |
| JP5256578B2 (ja) * | 2005-12-20 | 2013-08-07 | 大正製薬株式会社 | 掻痒性皮膚疾患の予防または治療剤 |
| TWI507528B (zh) | 2006-01-17 | 2015-11-11 | Somalogic Inc | 測試樣品的多重分析方法 |
| EP1996193A2 (en) | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| EP1897886A1 (en) * | 2006-09-08 | 2008-03-12 | Bayer Schering Pharma Aktiengesellschaft | Compounds as aptamer-dimers and their uses in diagnosis and therapy |
| US8242258B2 (en) * | 2006-12-03 | 2012-08-14 | Agilent Technologies, Inc. | Protecting groups for RNA synthesis |
| CA2673029C (en) | 2006-12-22 | 2017-03-28 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| EP2144921A2 (en) * | 2007-02-27 | 2010-01-20 | K.U. Leuven Research and Development | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
| US20090137506A1 (en) * | 2007-05-02 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| MX344253B (es) | 2007-07-17 | 2016-12-09 | Somalogic Inc | Metodo para generar aptameros con constantes de disociacion mejoradas. |
| US8404830B2 (en) | 2007-07-17 | 2013-03-26 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US20090215050A1 (en) | 2008-02-22 | 2009-08-27 | Robert Delmar Jenison | Systems and methods for point-of-care amplification and detection of polynucleotides |
| US8703416B2 (en) | 2008-07-17 | 2014-04-22 | Somalogic, Inc. | Method for purification and identification of sperm cells |
| JP5602020B2 (ja) * | 2008-09-24 | 2014-10-08 | 株式会社リボミック | Ｎｇｆに対するアプタマー及びその使用 |
| US20120322862A1 (en) | 2010-03-03 | 2012-12-20 | Somalogic, Inc. | Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders |
| WO2011119852A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| US9175292B2 (en) | 2010-03-24 | 2015-11-03 | Fujimoto Pharmaceutical Corporation | Aptamer for NGF and use thereof |
| US8598140B2 (en) | 2010-04-12 | 2013-12-03 | Somalogic, Inc. | Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders |
| WO2011130065A1 (en) | 2010-04-12 | 2011-10-20 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| CN103492569B (zh) * | 2010-11-05 | 2020-04-07 | 米拉根医疗公司 | 碱基经修饰的寡核苷酸 |
| EP2831278B1 (en) * | 2012-03-28 | 2019-05-08 | Somalogic, Inc. | Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions |
| CN105658658B (zh) | 2013-11-21 | 2019-11-05 | 私募蛋白质体公司 | 胞苷-5-甲酰胺修饰的核苷酸组合物及其相关方法 |
-
2011
- 2011-04-12 US US13/634,618 patent/US8598140B2/en active Active
- 2011-04-12 AU AU2011240774A patent/AU2011240774B2/en not_active Ceased
- 2011-04-12 ES ES11769451.3T patent/ES2667491T3/es active Active
- 2011-04-12 EP EP17200661.1A patent/EP3345915B1/en active Active
- 2011-04-12 NZ NZ602618A patent/NZ602618A/en not_active IP Right Cessation
- 2011-04-12 AR ARP110101235A patent/AR081452A1/es unknown
- 2011-04-12 EP EP11769393.7A patent/EP2558586B1/en not_active Not-in-force
- 2011-04-12 UA UAA201212806A patent/UA105290C2/ru unknown
- 2011-04-12 SG SG2012068565A patent/SG184089A1/en unknown
- 2011-04-12 WO PCT/US2011/032143 patent/WO2011130289A1/en not_active Ceased
- 2011-04-12 MX MX2012011779A patent/MX2012011779A/es not_active Application Discontinuation
- 2011-04-12 CN CN201180028946.3A patent/CN102985435B/zh active Active
- 2011-04-12 KR KR1020187006712A patent/KR101952671B1/ko active Active
- 2011-04-12 NO NO11769451A patent/NO2558478T3/no unknown
- 2011-04-12 DK DK11769451.3T patent/DK2558478T3/en active
- 2011-04-12 JP JP2013505029A patent/JP6012591B2/ja not_active Expired - Fee Related
- 2011-04-12 MX MX2016005612A patent/MX373860B/es unknown
- 2011-04-12 KR KR1020127029502A patent/KR101842269B1/ko active Active
- 2011-04-12 MX MX2020003168A patent/MX392756B/es unknown
- 2011-04-12 EP EP11769451.3A patent/EP2558478B1/en active Active
- 2011-04-12 BR BR122021003805A patent/BR122021003805B8/pt active IP Right Grant
- 2011-04-12 CA CA2793451A patent/CA2793451A1/en not_active Abandoned
- 2011-04-12 ES ES17200661T patent/ES2905656T3/es active Active
- 2011-04-12 JP JP2013505056A patent/JP5901610B2/ja active Active
- 2011-04-12 MY MYPI2012004319A patent/MY160608A/en unknown
- 2011-04-12 CN CN201610828700.9A patent/CN107033204A/zh active Pending
- 2011-04-12 US US13/085,256 patent/US20110275794A1/en not_active Abandoned
- 2011-04-12 KR KR1020197004119A patent/KR102185779B1/ko active Active
- 2011-04-12 MX MX2012011771A patent/MX2012011771A/es active IP Right Grant
- 2011-04-12 KR KR1020127026771A patent/KR20130043099A/ko not_active Ceased
- 2011-04-12 SG SG2012074647A patent/SG184497A1/en unknown
- 2011-04-12 BR BR112012025872A patent/BR112012025872B8/pt active IP Right Grant
- 2011-04-12 CA CA2797188A patent/CA2797188C/en active Active
- 2011-04-12 CN CN201180018781.1A patent/CN102858990B/zh not_active Expired - Fee Related
- 2011-04-12 PH PH1/2012/501838A patent/PH12012501838A1/en unknown
- 2011-04-12 WO PCT/US2011/032017 patent/WO2011130195A1/en not_active Ceased
- 2011-04-12 AU AU2011240677A patent/AU2011240677B2/en active Active
- 2011-04-12 ES ES11769393.7T patent/ES2610159T3/es active Active
- 2011-04-12 CA CA3066785A patent/CA3066785A1/en active Pending
- 2011-04-12 EA EA201291034A patent/EA022429B1/ru not_active IP Right Cessation
- 2011-04-12 TW TW100112666A patent/TWI505833B/zh not_active IP Right Cessation
- 2011-04-12 CN CN201410340470.2A patent/CN104069512A/zh active Pending
- 2011-04-12 SG SG2014006522A patent/SG2014006522A/en unknown
- 2011-10-11 TW TW105113101A patent/TWI593701B/zh active
- 2011-10-11 TW TW109100780A patent/TW202019943A/zh unknown
- 2011-10-11 TW TW106114660A patent/TWI643864B/zh active
- 2011-10-11 TW TW108120336A patent/TWI684596B/zh active
- 2011-10-11 TW TW107132304A patent/TWI671309B/zh active
-
2012
- 2012-10-10 IL IL222339A patent/IL222339A/en active IP Right Grant
- 2012-10-12 CO CO12181026A patent/CO6630139A2/es unknown
-
2013
- 2013-11-01 US US14/069,798 patent/US9163056B2/en active Active
-
2015
- 2015-03-06 HK HK15102316.6A patent/HK1201740A1/xx unknown
- 2015-09-08 US US14/847,150 patent/US20150376223A1/en not_active Abandoned
- 2015-10-12 IL IL242038A patent/IL242038A/en active IP Right Grant
-
2016
- 2016-03-04 JP JP2016041782A patent/JP6352324B2/ja active Active
- 2016-04-04 US US15/090,406 patent/US20160355540A1/en not_active Abandoned
-
2017
- 2017-06-06 IL IL252703A patent/IL252703A/en active IP Right Grant
- 2017-07-14 US US15/650,281 patent/US10221207B2/en active Active
- 2017-11-30 IL IL256014A patent/IL256014B/en active IP Right Grant
- 2017-11-30 IL IL256013A patent/IL256013B/en active IP Right Grant
-
2018
- 2018-02-28 JP JP2018034436A patent/JP7025818B2/ja active Active
-
2019
- 2019-01-22 US US16/254,127 patent/US20190233461A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523887A5 (enExample) | ||
| TWI603970B (zh) | 雜環化合物之合成 | |
| JPWO2012043730A1 (ja) | モルホリノ核酸誘導体 | |
| JP2012532199A5 (enExample) | ||
| JP2010512169A5 (enExample) | ||
| JP6307087B2 (ja) | ベンズアミド化合物の合成に有用な化合物 | |
| JP2017518966A5 (enExample) | ||
| CA2908379C (en) | Photoresponsive nucleotide analogue having photocrosslinking ability | |
| JP2006514038A5 (enExample) | ||
| US10138224B2 (en) | Preparation method of rociletinib | |
| KR20220017898A (ko) | 아미노피리미딘 화합물의 제조 방법 | |
| WO2019021945A1 (ja) | 可視光域で光架橋可能な光応答性ヌクレオチドアナログ | |
| JP7186165B2 (ja) | 可視光域で光架橋可能な光応答性ヌクレオチドアナログ | |
| JP4887500B2 (ja) | ヌクレオシド類似体またはその塩 | |
| JP7298866B2 (ja) | 核酸合成用固相担体及びそれを用いた核酸の製造方法 | |
| JP2000327694A (ja) | ヌクレオシド化合物 | |
| JP2023065526A (ja) | 酸性官能基のアルキル化方法 | |
| JP2001517659A5 (enExample) | ||
| JP6175136B2 (ja) | ２，２−ジフルオロエチルアミンをアルキル化することによる２，２−ジフルオロエチルアミン誘導体の調製方法 | |
| Awad et al. | A convenient synthesis of the cytidyl 3′-terminal monomer for solid-phase synthesis of RNG oligonucleotides | |
| JP4797156B2 (ja) | リボヌクレオシドの２’水酸基の脱保護方法 | |
| US6822090B2 (en) | Process for the preparation of cytidine derivatives | |
| JP7423533B2 (ja) | 配糖体化合物の製造方法 | |
| JP2015524846A5 (enExample) | ||
| WO2010079813A1 (ja) | イノシン誘導体の製造方法 |